Manhattan Research Ranks the Top Pharmaceutical Branded Websites by Rx Request Rates

Manhattan Research Ranks the Top Pharmaceutical Branded Websites by Rx Request Rates

NEW YORK, Feb 04, 2008 -- Manhattan Research, a leader in syndicated research and marketing services for the health and pharmaceutical industry, today revealed the top pharmaceutical branded product websites ranked by offline requests by U.S. adult consumers. The product site rankings are based on the comprehensive online consumer research study with 5,112 U.S. adults titled ePharma Consumer(R: 58.03, -0.38, -0.65%) v7.0: The Future of Integrated DTC Marketing. In addition to the top product site rankings, the study provides in-depth data on more than 200 leading pharmaceutical product sites including site satisfaction, site search rationales, tools and features desired on product sites, and a wide range of consumer actions taken afterwards.

"Having the most unique visitors is no longer the ultimate goal of a successful pharmaceutical product site," says Mark Bard, president of Manhattan Research. He continues, "Brand teams and agencies are being challenged to demonstrate the economic and strategic value created by these online destinations - beyond the raw number of visitors or page views. After all, if a site is all traffic and no action then what is the strategic value of the site?"

    Top 10 Pharmaceutical Branded Websites Driving Prescription Drug Requests

      1.  Chantix
      2.  Cialis
      3.  Viagra
      4.  Aciphex
      5.  Ambien CR
      6.  Levitra
      7.  Lamisil
      8.  Lunesta
      9.  Wellbutrin XL
     10.  Ortho Evra

    Source: ePharma Consumer(R: 58.03, -0.38, -0.65%) v7.0, Manhattan Research, LLCTo learn more about consumer segments of pharmaceutical information seekers, contact Manhattan Research by visiting www.manhattanresearch.com/ePC.htm or by emailing [email protected].

Some of the additional product sites researched within ePharma Consumer(R: 58.03, -0.38, -0.65%) v7.0 include the following: Abilify, Actonel, Advair, Aranesp, Aricept, Avandia, Boniva, Botox, Caduet, Concerta, Crestor, Cymbalta, Depakote, Depo- Provera, Detrol LA, Effexor XR, Enbrel, Flomax, Flonase, Flovent, Fosamax, Gardasil, Glucophage XR, Humira, Humulin, Imitrex, Lantus, Lexapro, Lipitor, Nasacort, Nasonex, Neulasta, Neurontin, Nexium, Norvasc, NuvaRing, Ortho Tri- Cyclen Lo, Paxil, Plavix, Pravachol, Prevacid, Protonix, Provigil, Pulmicort, Restasis, Risperdal, Rozerem, Seasonale, Seroquel, Singulair, Strattera, Tamiflu, Topamax, Toprol XL, Tricor, Valtrex, Vytorin, Yasmin, Yaz, Zocor, Zoloft, Zomig, Zyprexa and Zyrtec.

Please visit www.manhattanresearch.com/ePC.htm to download the ePharma Consumer(R: 58.03, -0.38, -0.65%) product brochure, request subscription information, and to listen to two audio presentations summarizing highlights from the research.

Manhattan Research

ePharma Consumer(R: 58.03, -0.38, -0.65%) v7.0 is a syndicated multi-client study and advisory service focused on key research topics and trends impacting online U.S. consumers seeking pharmaceutical information. The study was fielded in December 2007 among 5,112 U.S. adult consumers. In addition to ePharma Consumer(R: 58.03, -0.38, -0.65%), Manhattan Research conducts five additional research studies annually among consumers and physicians in the United States and in Europe: Cybercitizen(R: 58.03, -0.38, -0.65%) Health US, Cybercitizen(R: 58.03, -0.38, -0.65%) Health Europe, Taking the Pulse(R: 58.03, -0.38, -0.65%) US, Taking the Pulse(R: 58.03, -0.38, -0.65%) Europe, and ePharma Physician(R: 58.03, -0.38, -0.65%). Each study serves a unique purpose and focuses on specific aspects of information technology adoption. Broad consumer and physician research is complemented by targeted analyses among more than 50 consumer therapeutic segments and 25 physician specialist segments.

Suggested Articles

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.